Literature DB >> 25661686

The chemokine ligand CXCL16 is an indicator of bacterial infection in necrotizing pancreatitis.

Uwe A Wittel1, Andrea I Schmidt2, Philipp J Poxleitner2, Gabriel J Seifert2, Sophia Chikhladze2, Pauli Puolakkainen3, Ulrich T Hopt2, Leena Kylänpää3.   

Abstract

OBJECTIVES: Current guidelines tell us that intervention in severe necrotizing pancreatitis ought to be performed as late as possible. However, when pancreatic necrosis becomes infected, the necrotic tissue needs to be removed. Unfortunately, bacterial infection can only be proven by invasive methods.
METHODS: Necrotizing pancreatitis with sterile or infected necrosis was induced in mice. Mice serum samples were examined by antibody-based protein array. After identifying candidate proteins that showed strong regulation, the serum concentration of these proteins was examined by sandwich ELISA. Then, human serum samples were collected from patients with mild pancreatitis, severe pancreatitis with and without pancreatic necrosis and patients with microbiologically proven infection of pancreatic necrosis. These serum samples were then analyzed by sandwich ELISA.
RESULTS: In mice 6 proteins were strongly up-regulated and were further investigated by ELISAs. Of these proteins, CXCL16 and TRANCE (RANKL) concentrations were analyzed in human serum samples. CXCL16 and TRANCE were increased in patients with pancreatic necrosis and abdominal infection. Receiver operated characteristics showed that CXCL16 was superior in predicting infected pancreatic necrosis when compared to C-reactive protein and TRANCE.
CONCLUSIONS: Serum CXCL16 is increased in severe pancreatitis with infected pancreatic necrosis and identifies patients who benefit from surgical necrosectomy.
Copyright © 2015 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; CXCL16; Chemokine; Infected necrosis; Infection; Mortality; Necrosis; Necrotizing pancreatitis; SIRS; Systemic inflammatory response syndrome

Mesh:

Substances:

Year:  2015        PMID: 25661686     DOI: 10.1016/j.pan.2015.01.004

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

Review 1.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

2.  Aqueous humor cytokine profiling in patients with wet AMD.

Authors:  Fang Liu; Xiaoyan Ding; Yu Yang; Jiaqing Li; Miao Tang; Miner Yuan; Andina Hu; Zongyi Zhan; Zijing Li; Lin Lu
Journal:  Mol Vis       Date:  2016-04-22       Impact factor: 2.367

3.  Chemokine CXCL16 mediates acinar cell necrosis in cerulein induced acute pancreatitis in mice.

Authors:  Yojiro Sakuma; Yuzo Kodama; Takaaki Eguchi; Norimitsu Uza; Yoshihisa Tsuji; Masahiro Shiokawa; Takahisa Maruno; Katsutoshi Kuriyama; Yoshihiro Nishikawa; Yuki Yamauchi; Motoyuki Tsuda; Tatsuki Ueda; Tomoaki Matsumori; Toshihiro Morita; Teruko Tomono; Nobuyuki Kakiuchi; Atsushi Mima; Yuko Sogabe; Saiko Marui; Takeshi Kuwada; Akihiko Okada; Tomohiro Watanabe; Hiroshi Nakase; Tsutomu Chiba; Hiroshi Seno
Journal:  Sci Rep       Date:  2018-06-11       Impact factor: 4.379

4.  New strategies for Leptospira vaccine development based on LPS removal.

Authors:  Fabiana Lauretti-Ferreira; Paloma L D Silva; Naiara M Alcântara; Bruna F Silva; Isabele Grabher; Gisele O Souza; Erika Nakajima; Milena A Akamatsu; Silvio A Vasconcellos; Patricia A E Abreu; Eneas Carvalho; Elizabeth A L Martins; Paulo L Ho; Josefa B da Silva
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240

5.  Heightened Levels of Antimicrobial Response Factors in Patients With Rheumatoid Arthritis.

Authors:  Prathapan Ayyappan; Robert Z Harms; Jennifer A Seifert; Elizabeth A Bemis; Marie L Feser; Kevin D Deane; M Kristen Demoruelle; Ted R Mikuls; V Michael Holers; Nora E Sarvetnick
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.